Precisely controlling exposure is critical to maximizing efficacy and minimizing risk. This session explores how KinetiSol™-enabled bioavailability enhancement (BAE) and controlled-release (CR) design enable next-generation PK optimization. Learn how high-energy amorphous processing and formulation tuning can rapidly shape exposure profiles—improving absorption, extending duration, and aligning PK with therapeutic intent for challenging APIs.
